Tumor imaging is primarily used for response assessment, yet mounting evidence suggests that tumor burden (TB) not only represents a prognostic biomarker at baseline (5–8), but also a means to dynamically assess disease response in the context of CD19 CART (9, 10). The gene discussed is CD19; the disease is neoplasm.